Form 4: AN2 Therapeutics Director Acquires Shares
Insider Transaction Filing
AN2 Therapeutics, Inc. reports a Form 4 filing detailing share acquisition by Director Aziz Kabeer.
Summary
- Aziz Kabeer, a Director at AN2 Therapeutics, Inc., acquired 3,775 shares of common stock on April 10, 2026.
- These shares were issued in lieu of cash compensation under the company's non-employee director compensation policy and vested immediately.
- Following this transaction, Kabeer directly owns 56,254 shares.
- Additionally, Kabeer is associated with indirect beneficial ownership of 1,995,958 shares held by Adjuvant Global Health Technology Fund, L.P. and 377,542 shares held by Adjuvant Global Health Technology Fund DE, L.P.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation-related share issuance to a director rather than a discretionary purchase or sale that might signal a stronger view on the company's prospects.
Positives
- Director Aziz Kabeer has increased his direct beneficial ownership of AN2 Therapeutics stock.
- The acquisition of shares was part of the company's compensation policy for non-employee directors, indicating alignment of director interests with the company.
- All acquired shares vested immediately, suggesting no further holding periods are required for these specific shares.
Future Outlook
This filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. This specific filing indicates a director's compensation being settled in equity.
Stakeholder Impact
- Shareholders: Increased transparency into director holdings and compensation structure.
- Employees: Indirect impact through director compensation alignment with equity.
Key Dates
| Date | Description |
|---|---|
| 04/10/2026 | Transaction Date for share acquisition by Aziz Kabeer and earliest transaction date. |
Keywords
AN2 Therapeutics, ANTX, Form 4, Director, Share Acquisition, Beneficial Ownership, Compensation Policy, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.